The aim of this study was to identify risk factors for acquisition of intra-abdominal infections (IAI) caused by carbapenemase-producing Enterobacteriaceae (CPE) in surgical patients.
Methods:
A matched case-control study was performed. We included all cases with CPE-related IAI acquired during admission to a general surgery department from January 2013 to December 2018, and they were matched with control subjects with IAI caused by non-resistant bacteria (ratio 1:3). Independent risk factors were obtained by logistic regression.
Results:
Forty patients with IAI-CPE were matched with 120 control subjects. Independent risk factors for acquisition of IAI-CPE were previous hospitalization (odds ratio [OR] 2.56; 95% confidence interval [CI] l 1.01–6.49; p = 0.047), digestive endoscopy (OR 4.11; 95% CI 1.40–12.07; p = 0.010), carbapenem therapy (OR 9.54; 95% CI 3.33–27.30; p < 0.001), and aminoglycoside use (OR 45.41; 95% CI 7.90–261.06; p < 0.001).
Conclusions:
Four clinical factors can identify patients at high-risk of IAI-CPE.
Get full access to this article
View all access options for this article.
References
1.
BrolundA, LagerqvistN, ByforsS, et al.Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe: Assessment by national experts from 37 countries, July 2018. Eur Surveill, 2019; 24:1900123.
2.
GrundmannH, GlasnerC, AlbigerB, et al.Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): A prospective, multinational study. Lancet Infect Dis, 2017; 17:153–163.
3.
TacconelliE, CarraraE, SavoldiA, et al.Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis, 2018; 18:318–327.
4.
BartschSM, McKinnellJA, MuellerLE, et al.Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect, 2017;23:48 e9–e16.
5.
MartinA, FahrbachK, ZhaoQ, LodiseT. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: Results of a systematic literature review and meta-analysis. Open Forum Infect Dis, 2018; 5:ofy150.
6.
OtterJA, BurgessP, DaviesF, et al.Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: An economic evaluation from a hospital perspective. Clin Microbiol Infect, 2017; 23:188–196.
7.
Pano PardoJR, Serrano VillarS, Ramos RamosJC, PintadoV. Infections caused by carbapenemase-producing Enterobacteriaceae: Risk factors, clinical features and prognosis. Enferm Infecc Microbiol Clin, 2014; 32(Suppl 4):41–48.
8.
van LoonK, Voor In 't HoltAF, VosMC. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2018; 62:e01730-17.
9.
Di CarloP, GulottaG, CasuccioA, et al.KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: Analysis of a case series of 30 patients. BMC Anesthesiol, 2013; 13:13.
10.
Di CarloP, PantusoG, CusimanoA, et al.Two cases of monomicrobial intraabdominal abscesses due to KPC–3 Klebsiella pneumoniae ST258 clone. BMC Gastroenterol, 2011; 11:103.
11.
Di CarloP, VitaleF, O'SuilleabhainC, CasuccioA. Management of intra-abdominal infections due to carbapenemase-producing organisms. Curr Infect Dis Rep, 2014; 16:428.
12.
GiannellaM, TrecarichiEM, De RosaFG, et al.Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: A prospective observational multicentre study. Clin Microbiol Infect, 2014; 20:1357–1362.
13.
LiY, ShenH, ZhuC, YuY. Carbapenem-resistant Klebsiella pneumoniae Infections among ICU admission patients in central China: Prevalence and prediction model. Biomed Res Int, 2019; 2019:9767313.
14.
TumbarelloM, TrecarichiEM, TumiettoF, et al.Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother, 2014; 58:3514–3520.
15.
MazuskiJE, TessierJM, MayAK, SawyerRG. Response to “re-thinking the definition of complicated intra-abdominal infection.”. Surg Infect, 2017; 18:375–376.
16.
MazuskiJE, TessierJM, MayAK, et al.The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. Surg Infect, 2017; 18:1–76.
17.
DrippsRD. New classification of physical status. Anesthesiology, 1963; 24:111.
18.
DindoD, DemartinesN, ClavienPA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg, 2004; 240:205–213.
GarnerJS, JarvisWR, EmoriTG, et al.CDC definitions for nosocomial infections, 1988. Am J Infect Control, 1988; 16:128–140.
21.
LevyMM, FinkMP, MarshallJC, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 2003; 31:1250–1256.
22.
HoranTC, AndrusM, DudeckMA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008; 36:309–332.
23.
ZarkotouO, PournarasS, TseliotiP, et al.Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect, 2011; 17:17981–17983.
24.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. M100-S25. Wayne, PA: The Institute, 2015.
Mediavilla-GradolphC, Sainz-RodriguezR, Valverde-TroyaM, et al.[Evaluation of an immunochromatographic test for the detection of OXA-48 carbapenemase] (Spa). Rev Esp Quimioter, 2017; 30:45–49.
28.
TatoM, Ruiz-GarbajosaP, TraczewskiM, et al.Multisite evaluation of Cepheid Xpert Carba-R Assay for detection of carbapenemase-producing organisms in rectal swabs. J Clin Microbiol, 2016; 54:1814–1819.
29.
PeduzziP, ConcatoJ, KemperE, et al.A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol, 1996; 49:1373–1379.
30.
GiannellaM, BartolettiM, MorelliMC, et al.Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: The importance of pre- and posttransplant colonization. Am J Transplant, 2015; 15:1708–1715.
31.
MasedaE, SalgadoP, AnilloV, et al.Risk factors for colonization by carbapenemase-producing enterobacteria at admission to a surgical ICU: A retrospective study. Enferm Infecc Microbiol Clin, 2017; 35:333–337.
32.
TumbarelloM, TrecarichiEM, De RosaFG, et al.Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study. J Antimicrob Chemother, 2015; 70:2133–2143.
33.
GiannellaM, PascaleR, Gutierrez-GutierrezB, et al.The use of predictive scores in the management of patients with carbapenem-resistant Klebsiella pneumoniae infection. Expert Rev Anti Infect Ther, 2019; 17:265–273.
34.
TartofSY, KuntzJL, ChenLH, et al.Development and assessment of risk scores for carbapenem and extensive beta-lactam resistance among adult hospitalized patients with Pseudomonas aeruginosa nfection. JAMA Netw Open, 2018; 1:e183927.
35.
GiacobbeDR, Del BonoV, TrecarichiEM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: Results from a multicenter case-control-control study. Clin Microbiol Infect 2015;21:1106 e1–e8.
36.
El-KholyAA, ElananyMG, SherifMM, GadMA. High prevalence of VIM, KPC, and NDM expression among surgical site infection pathogens in patients having emergency surgery. Surg Infect, 2018; 19:629–633.
37.
O'HoroJC, FarrellA, SohailMR, SafdarN. Carbapenem-resistant Enterobacteriaceae and endoscopy: An evolving threat. Am J Infect Control, 2016; 44:1032–1036.
38.
DevereauxBM, AthanE, BrownRR, et al.Australian infection control in endoscopy consensus statements on carbapenemase-producing Enterobacteriaceae. J Gastroenterol Hepatol, 2019; 34:650–658.
39.
RutalaWA, WeberDJ. Outbreaks of carbapenem-resistant Enterobacteriaceae infections associated with duodenoscopes: What can we do to prevent infections?. Am J Infect Control, 2016; 44(5Suppl):e47–e51.
40.
Papadimitriou-OlivgerisM, MarangosM, ChristofidouM, et al.Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. Scand J Infect Dis, 2014; 46:642–648.
41.
SoubirouJF, GaultN, AlfaiateT, et al.Ventilator-associated pneumonia due to carbapenem-resistant gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii. Scand J Infect Dis, 2014; 46:215–220.
42.
ZhengSH, CaoSJ, XuH, et al.Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: A three-year retrospective study in a large tertiary hospital in Northern China. Infect Dis, 2018; 50:443–451.
43.
KumarA, SafdarN, KethireddyS, ChateauD. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study. Crit Care Med, 2010; 38:1651–1664.
IredellJ, BrownJ, TaggK. Antibiotic resistance in Enterobacteriaceae: Mechanisms and clinical implications. BMJ, 2016; 352:h6420.
48.
MittalG, GaindR, KumarD, et al.Risk factors for fecal carriage of carbapenemase producing Enterobacteriaceae among intensive care unit patients from a tertiary care center in India. BMC Microbiol, 2016; 16:138.
49.
Mora-GuzmanI, Rubio-PerezI, Maqueda GonzalezR, et al.Surgical site infection by carbapenemase-producing Enterobacteriaceae. A challenge for today's surgeons. Cir Esp, 2020; 98:342–349.
50.
MagiorakosAP, BurnsK, Rodriguez BanoJ, et al.Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control, 2017; 6:113.
